Epirubicin and cyclophosphamide followed by docetaxel as primary systemic chemotherapy in locally advanced breast cancer

Anticancer Research

Volumn 28, Issue 6 B, 2008, Pages 4137-4142

  Hirano, Akira ^a   Shimizu, Tadao ^a,b   Watanabe, Osamu ^a   Kinoshita, Jun ^a   Kimura, Kiyomi ^a   Kamimura, Mari ^a   Domoto, Kaoru ^a   Aiba, Motohiko ^a   Ogawa, Kenji ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^b NONE   (Japan)

Author keywords

Breast cancer; Docetaxel; Epirubicin; Primary systemic chemotherapy

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; EPIRUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG ACTIVITY; DRUG TOLERABILITY; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HISTOPATHOLOGY; HUMAN; LEUKOPENIA; LUNG TOXICITY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SENSORY NEUROPATHY; SIDE EFFECT; TASTE DISORDER; THROMBOCYTOPENIA; TREATMENT RESPONSE; TUMOR VOLUME; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CYCLOPHOSPHAMIDE; DRUG ADMINISTRATION SCHEDULE; EPIRUBICIN; FEMALE; HUMANS; MIDDLE AGED; TAXOIDS;

EID: 58149163571     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Hortobagyi GN: Comprehensive management of locally advanced breast cancer. Cancer 66: 1387-1391, 1990.
2. Bear HD: Indications for neoadjuvant chemotherapy for breast cancer. Semin Oncol 25: 3-12, 1998.
3. Kaufmann M, von Minckwitz G, Smith R, Valero V, Gianni L. Eiermann W, Howell A, Costa SD, Beuzeboc P, Untch M, Blohmer JU, Sinn HP, Sittek R, Souchon R, Tulusan AH, Volm T and Senn HJ: International Expert Panel on the use of primary (preoperative) systemic treatment of operable breast cancer: review and recommendations. J Clin Oncol 21: 2600-2608, 2003.
4. Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thurlimann B and Senn HJ: Meeting highlights: updated International Expert Consensus on the primary therapy of early breast cancer. J Clin Oncol 21: 3357-3365, 2003.
5. Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thurlimann B and Senn HJ: Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol 18: 1133-1144, 2007.
6. Fisher B, Bryant J, Wolmark N, Mamounas E, Brown A, Fisher ER, Wickerham DL, Begovic M, DeCillis A, Robidoux A, Margolese RG, Cruz AB Jr, Hoehn JL, Lees AW, Dimitrov NV and Bear HD: Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 16: 2672-2685, 1998.
7. Belembaogo E, Feillel V, Chollet P, Cure H, Verrelle P, Kwiatkowski F, Achard JL, Le Bouedec G, Chassagne J and Bignon YJ: Neoadjuvant chemotherapy in 126 operable breast cancers. Eur J Cancer 28A: 896-900, 1992.
8. van der Hage JA, van de Velde CJ, Julien JP, Tubiana-Hulin M, Vanderveiden C, Duchateau L and Cooperating investigators: Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902. J Clin Oncol 19: 4224-4237, 2001.
9. Kuerer HM, Newman LA, Smith TL, Ames FC, Hunt KK, Dhingra K, Theriault RL, Singh G, Binkley SM, Sneige N, Buchholz TA, Ross MI, McNeese MD, Buzdar AU, Hortobagyi GN and Singletary SE: Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 17: 460-469, 1999.
10. Fumoleau P, Chevallier B, Kerbrat P, Krakowski Y, Misset JL, Maugard-Louboutin C, Dieras V, Azli N, Bougon N, Riva A and Roche H: A multicentre phase II study of the efficacy and safety of docetaxel as first-line treatment of advanced breast cancer: report of the Clinical Screening Group of the EORTC. Ann Oncol 7: 165-171, 1996.
11. Amat S, Bougnoux P, Penault-Llorca F, Fetissof F, Cure H, Kwiatkowski F, Achard JL, Body G, Dauplat J and Chollet P: Neoadjuvant docetaxel for operable breast cancer induces a high pathological response and breast-conservation rate. Br J Cancer 88: 339-1345, 2003.
12. Sjostrom J, Blomqvist C, Mouridsen H, Pluzanska A, Ottosson-Lonn S, Bengtsson NO, Ostenstad B, Mjaaland I, Palm-Sjovall M, Wist E, Valvere V, Anderson H and Bergh J: Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: a randomised phase III study with crossover on progression by the Scandinavian Breast Group. Eur J Cancer 35: 1194-1201, 1999.
13. Nabholtz JM, Senn HJ, Bezwoda WR, Melnychuk D, Deschenes L, Douma J, Vandenberg TA, Rapoport B, Rosso R, Trillet-Lenoir V, Drbal J, Molino A, Nortier JW, Richel DJ, Nagykalnai T, Siedlecki P, Wilking N, Genot JY, Hupperets PS, Pannuti F, Skarlos D, Tomiak EM, Murawsky M, Alakl M and Aapro M: Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group. J Clin Oncol 17: 1413-1424, 1999.
14. Bonneterre J, Dieras V, Tubiana-Hulin M, Bougnoux P, Bonneterre ME, Delozier T, Mayer F, Culine S, Dohoulou N and Bendahmane B: Phase II multicentre randomised study of docetaxel plus epirubicin vs. 5-fluorouracil plus epirubicin and cyclophosphamide in metastatic breast cancer. Br J Cancer 91: 1466-1471, 2004.
15. Pagani O, Sessa C, Martinelli G, Crivellari D, Buonadonna A, Thurlimann B, Hess D, Borner M, Bauer J, Zampino G, Zimatore M, Graffeo R, Riva A and Goldhirsch A: Dose-finding study of epirubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer. Ann Oncol 10: 539-545, 1999.
16. Ganem G, Tubiana-Hulin M, Fumoleau P, Combe M, Misset JL, Vannetzel JM, Bachelot T, De Ybarlucea LR, Lotz V, Bendahmane B and Dieras V: Phase II trial combining docetaxel and doxorubicin as neoadjuvant chemotherapy in patients with operable breast cancer. Ann Oncol 14: 1623-1628, 2003.
17. de Matteis A, Nuzzo F, D'Aiuto G, Labonia V, Landi G, Rossi E, Mastro AA, Botti G, De Maio E and Perrone F: Docetaxel plus epidoxorubicin as neoadjuvant treatment in patients with large operable or locally advanced carcinoma of the breast: a single-center, phase II study. Cancer 94: 895-901, 2002.
18. Matsuo K, Fukutomi T, Watanabe T, Hasegawa T, Tsuda H and Akashi-Tanaka S: Concordance in pathological responses to neoadjuvant chemotherapy between invasive and noninvasive components of primary breast carcinomas. Breast Cancer 9: 75-81, 2002.
19. Toi M, Nakamura S, Kuroi K, Iwata H, Ohno S, Masuda N, Kusama M, Yamazaki K, Hisamatsu K, Sato Y, Kashiwaba M, Kaise H, Kurosumi M, Tsuda H, Akiyama F, Ohashi Y, Takatsuka Y; for Japan Breast Cancer Research Group (JBCRG): Phase II study of preoperative sequential FEC and docetaxel predicts of pathological response and disease-free survival. Breast Cancer Res Treat 110: 531-539, 2008.
20. von Minckwitz G, Raab G, Caputo A, Schutte M, Hilfrich J, Blohmer JU, Gerber B, Costa S, Merkle E, Eidtmann H, Lampe D, Jackisch C, du Bois A and Kaufmann M: Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group. J Clin Oncol 23: 2676-2685, 2005.
21. Jackisch C, von Minckwitz G, Eidtmann H, Costa SD, Raab G, Blohmer JU, Schutte M, Gerber B, Merkle E, Gademann G, Lampe D, Hilfrich J, Tulusan AH, Caputo A and Kaufmann M: Dose-dense biweekly doxorubicin/docetaxel versus sequential neoadjuvant chemotherapy with doxorubicin/cyclophosphamide/docetaxel in operable breast cancer: second interim analysis. Clin Breast Cancer 3: 276-280, 2002.
22. Bear HD, Anderson S, Smith RE, Geyer CE Jr, Mamounas EP, Fisher B, Brown AM, Robidoux A, Margolese R, Kahlenberg MS, Paik S, Soran A, Wickerham DL and Wolmark N: Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 24: 2019-2027, 2006.
23. Bear H, Anderson S, Brown A, Smith R, Mamounas EP, Fisher B, Margolese R, Theoret H, Soran A, Wickerham DL and Wolmark N: The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: Preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 21: 4165-4174, 2003.
24. Sobin LH and Wittekind CH: Breast tumors. In: TNM Classification of Malignant Tumours, 6th edition. New York, Wiley-Liss Inc., pp. 131-141, 2002.
25. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC and Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-216, 2000.
26. Kurosumi M, Akiyama F, Iwase T, Motomura K, Okazaki M and Tsuda H: Histopathological criteria for assessment of therapeutic response in breast cancer. Breast Cancer 1: 1-2, 2001.
27. National Cancer Institute. Common Treatment Criterion for Adverse Events Version 3.0. Available from URL: http://ctep.info.nih.gov/reporting/ctcnew.html [accessed Dec 12, 2003].
28. Hirano A, Shimizu T, Imamura H, Watanabe O, Kinoshita J, Okabe T, Kimura K, Kamimura M, Domoto K, Aiba M and Ogawa K: The combination of epirubicin plus docetaxel as neoadjuvant chemotherapy in locally-advanced breast cancer. Anticancer Res 26: 581-584, 2006.
29. Adachi I, Watanabe T, Takashima S, Narabayashi M, Horikoshi N, Aoyama H and Taguchi T: A late phase II study of RP56976 (docetaxel) in patients with advanced or recurrent breast cancer. Br J Cancer 73: 210-216, 1996.
30. Buzdar AU, Ibrahim NK, Francis D, Booser DJ, Thomas ES, Theriault RL, Pusztai L, Green MC, Arun BK, Giordano SH, Cristofanilli M, Frye DK, Smith TL, Hunt KK, Singletary SE, Sahin AA, Ewer MS, Buchholz TA, Berry D and Hortobagyi GN: Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol 23: 3676-3685, 2005.